US20150238663A1 - Device viewable under an imaging beam - Google Patents
Device viewable under an imaging beam Download PDFInfo
- Publication number
- US20150238663A1 US20150238663A1 US14/709,220 US201514709220A US2015238663A1 US 20150238663 A1 US20150238663 A1 US 20150238663A1 US 201514709220 A US201514709220 A US 201514709220A US 2015238663 A1 US2015238663 A1 US 2015238663A1
- Authority
- US
- United States
- Prior art keywords
- stent
- image
- imaging
- coating layer
- single coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
- A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/1214—Coils or wires
- A61B17/12145—Coils or wires having a pre-set deployed three-dimensional shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3403—Needle locating or guiding means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B46/00—Surgical drapes
- A61B46/10—Surgical drapes specially adapted for instruments, e.g. microscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/02—Instruments for taking cell samples or for biopsy
- A61B10/0233—Pointed or sharp biopsy instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3415—Trocars; Puncturing needles for introducing tubes or catheters, e.g. gastrostomy tubes, drain catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/374—NMR or MRI
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/376—Surgical systems with images on a monitor during operation using X-rays, e.g. fluoroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3954—Markers, e.g. radio-opaque or breast lesions markers magnetic, e.g. NMR or MRI
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/10—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis
- A61B90/11—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
Definitions
- the present invention relates generally to surgery under image guided navigation and more particularly relates to a method, device and system for surgical implantation of a medical device or the like, and/or postoperative evaluation of an implanted medical device or the like under image guidance.
- MDCTA Multi-detector Computed Tomography Angiography
- endovascular therapy has ushered in a new age of minimally invasive vascular treatment.
- Endovascular devices have been rapidly developed and refined.
- Present technologies have enabled precise deployment of stents in much smaller arteries and have become more flexible and compliant so they can be navigated through tortuosities.
- the monitoring of these patients has become suboptimal because it relies on conventional angiography which is invasive and expensive. It also requires the patient to spend a full day removed from their daily activities. It also requires that some patients on anticoagulation briefly discontinue their therapy or be admitted to the hospital for an extended period of time.
- New MDCTA technology has not been widely used or validated for follow up.
- MDCTA is also non-invasive, requires a minimal amount of time and is less costly. MDCTA now has an axial resolution less than 0.5 mm and with the proposed development of new protocols and algorithms for image processing, this will be a superior tool to evaluate stenting and the etiology of any restenosis or stent failures. In particular, it will likely be able to separate negative remodeling from neointimal growth. It will also be able to evaluate for stent deformity and wall apposition as well as remodeling. MDCTA should also be applicable to other endovascular procedures such as follow up for aneurysm coilings.
- MDCTA reflects a number of advances in medical imaging that allow real time and/or three-dimensional image gathering under Computed Tomography (“CT”), Magnetic Resonance Imaging (“MRI”) or the like.
- CT scanners such as the Toshiba Acquillion multi detector are capable of generating images in three different areas at frame rates of 13 frames a second, to thereby generate a three-dimensional rendering of the target area.
- CT Angiography CTA
- CTP CT Perfusion
- MDCTA Due to these present limitations using MDCTA, it is common to rely on classical angiography for postoperative evaluation of endovascular procedures, yet such angiographic methods are invasive and expensive. In the USA, an angiogram can cost up to $8000.00, yet a corresponding MDCTA could be offered for as little as $400.00. Additionally, endovascular ultrasound has significant associated risks and is not suitable for the small intracranial vessels. In the end, it is believed that MDCTA has the potential to provide good visualization of the lumen as well as the arterial wall and stent. MDCTA actually visualizes the stent better than fluoroscopy and will likely prove to be the preferred technique when background subtraction is used to increase vascular conspicuity. It is also believed that MDCTA would also enable more precise outcome evaluation and allow for investigation of the underlying pathophysiology as well as evaluation of the stents and devices used.
- Biodegradable polymers release their loaded agents as they break down, while the matrix of non-biodegradable polymers remain intact even after all of the therapeutic agent has been released. These polymers release their loaded material by a process of either bulk erosion or surface erosion and diffusion or degradation.
- the polymers and co-polymers that are available at the present time include ethylene vinyl acetate (“EVAc”), a hydrophilic non biodegradable polymer, and biodegradable polymers such as hydrophobic polymers such as poly[BIS(p-carboxyphenoxy)]propane-sebacic acid (“PCPP:SA”), hydrophilic polymers and fatty acid dimer-sebacic acid (“FAD:SA”) polymers that deliver drugs including hydrophilic drugs and compounds
- a process such as lyophilization can be used to load the polymer with the desired compound or drug or compounds or drugs.
- a desired compound such as iodinated contrast material, and methyl chloride may undergo the lyophilization process to load the PCPP:SA with a material with the ability to attenuate x-ray radiation and be visible on a radiographic image.
- a medical device made from a material operable to perform a therapeutic function of the device and wherein the material allows three-dimensional visualization of a surrounding tissue when the medical device is inserted into the tissue and viewed under an imaging beam.
- the medical device can be a stent and the surrounding tissue can be a lumen of a blood vessel.
- the stent can have a coating of a radioopaque material prior to insertion such that the stent that can be viewed during a conventional angiographic x-ray DA/DSA insertion and wherein the coating diminishes after insertion such that the stent can be viewed under CT post insertion.
- the stent can be coated with at least one of an antibiotic and a chemotherapy drug.
- the stent can be coated with at least one drug selected from the group consisting of a drug that is therapeutically effective to decrease attachment of platelets to the stent and a drug that is therapeutically effective to decrease restenosis.
- the drug can be selected from the group consisting of aspirin, plavix or paclitaxel.
- the device can be selected from the group of devices for the treatment of obstruction due to clot, plaque, atheroma, tumours, and treatments involving intimal hyperplasia and recurrent stenosis.
- the material used to manufacture the medical device can be selected from the group consisting of plastic, composite carbon fiber and Inconel, nitinol, stainless steel, or a radio lucent material.
- the imaging system can be a substantially real-time CT machine, such as the Toshiba Acquillon.
- the medical device can have an image density of less than about 1200 Hounsfield Units.
- the image density can be less than about 900 Hounsfield Units.
- the image density can be less than about 700 Hounsfield Units.
- the image density can be less than about 400 Hounsfield Units.
- the medical device can be a microcoil and the surrounding tissue is an aneurysm repaired with the microcoil.
- the configuration and structure of the medical device can be chosen to combine with the properties of the chosen material to provide a reduced beam hardened artifact.
- the device is a stent and the struts of the stent can be aligned or otherwise configured to reduce the beam hardened artifact.
- an imaging processing unit for a CT machine comprising:
- the database of known medical devices can include at least one of a stent and a microcoil.
- the associated properties in the database can include a Hounsfield unit measurement of the device.
- FIG. 1 is a representation of an imaging system
- FIG. 2 is a side view of a prior art stent
- FIG. 3 is a representation of a beam hardened artifact caused by the prior art stent of FIG. 2 when viewed under the imaging system of FIG. 1 ;
- FIG. 4 shows the beam hardened artifact of FIG. 3 at a different angle
- FIG. 5 shows the beam hardened artifact of FIG. 4 at a different angle
- FIG. 6 a side view of a stent in accordance with an embodiment of the invention.
- FIG. 7 is a representation of the stent of FIG. 6 when viewed under the imaging system of FIG. 1 ;
- FIG. 8 shows a microcoil in accordance with another embodiment of the invention.
- FIG. 9 is a partial view of the microcoil of FIG. 8 ;
- FIG. 10 is a representation of a beam hardened artifact caused by a prior art microcoil when viewed under the imaging system of FIG. 1 ;
- FIG. 11 is a representation of the microcoil of FIG. 9 after insertion into a patient and when viewed under the imaging system of FIG. 1 ;
- FIG. 12 is a representation of a beam hardened artifact caused by a prior art carotid stent when viewed under the imaging system of FIG. 1 ;
- FIG. 13 is a representation of a carotid stent in accordance with another embodiment of the invention after the carotid stent has been inserted into a patient and when viewed under the imaging system of FIG. 1 .
- Imaging system 30 comprises a patient chamber 34 , an image processing unit 38 and a display 42 .
- Imaging system 30 can be based on any known or established imaging technology, but in a present embodiment is based on computed tomography (CT) having substantially the same functionality as a machine like the Toshiba Acquillon.
- CT computed tomography
- patient chamber 34 is operable to capture images of a patient P in at least three planes
- processing unit 38 is operable to assemble those captured images to present a three-dimensional rendering of a target area within patient P on display 42 .
- Images on display 42 can be navigated and/or viewed using the mouse and keyboard attached to processing unit 38 , allowing the user to view a target area within patient P from any number of views.
- image processing unit 38 can also be attached to other output devices in addition to display 42 , such as a printer. Further, image processing unit 38 also typically includes a fixed storage device (such as a hard drive), a removable storage device (such as CD-Rewriter, or a tape drive) and a network interface card or other network interface means for connecting processing unit 38 to a network such as an intranet and/or the internet over which captured images can be delivered.
- a fixed storage device such as a hard drive
- a removable storage device such as CD-Rewriter, or a tape drive
- network interface card or other network interface means for connecting processing unit 38 to a network such as an intranet and/or the internet over which captured images can be delivered.
- FIG. 2 shows stent 50 in isolation, however, for purposes of explaining the prior art, it is to be assumed that stent 50 has been implanted in a coronary artery of patent P.
- FIG. 3 shows an image 54 rendered on display 42 of system 30 of patient P.
- Image 54 shows a beam hardened artefact 52 as it is implanted inside a coronary artery 58 inside a heart 62 of patient P.
- the area identified as beam hardened artefact 52 is an inaccurate reproduction of stent 50 as it is implanted inside artery 58 .
- the beam hardening artefact 52 is created by the material of stent 50 . Accordingly, system 30 is of limited value in performing post-operative evaluations of stent 50 and for determining whether any restenosis has occurred of coronary artery 58 .
- FIGS. 4 and 5 show additional images 54 a and 54 b , respectively, of different orientations of heart 62 , which are readily produced on display 42 due to the imaging capability of system 30 .
- stent 50 and the surrounding artery 58 are inaccurately reproduced due to beam hardening artefact 52 of stent 50 .
- system 30 in its current form stent 50 and system 30 do not provide meaningful images for post-operative evaluation of artery 58 and the progress of any restenosis that may be occurring in the lumen of artery 58 surrounding stent 50 .
- FIG. 6 shows a medical device in accordance with an embodiment of the invention as a stent 150 .
- Stent 150 from outward appearances is substantially the same as prior art stent 50 , and indeed, in the present embodiment is designed to provide substantially the same mechanical and therapeutic functionality as prior art stent 50 .
- stent 150 is made from a material that has a selected radiopacity such that the appearance of stent 150 is preserved when stent 150 is exposed to the imaging beam of system 30 and presented on display 42 .
- presence or absence of a beam hardening artefact can be measured according to the properties of the imaging system being used and in relation to the Hounsfield units associated with the particular material or tissue being exposed to the imaging beam.
- a relation between the linear attenuation coefficient (.mu.) and the corresponding Hounsfield unit (H) can be expressed as:
- the value of the Hounsfield unit varies from ⁇ 1000 (for air) to 1000 (for bone) to 3000, as more particularly shown in Table I.
- stent 150 in certain imaging systems materials with Hounsfield units exceeding about 1000 can be prone to creating beam hardening artefacts.
- presently preferred materials from which stent 150 can be manufactured to have reduced beam hardening artefacts include certain plastic, composite carbon fiber and Inconel metals that have similar mechanical properties to prior art stent 50 such that substantially the same therapeutic effect in stent 150 is achieved as was available in prior art stent 50 .
- the chosen material for stent 150 has a level of Hounsfield density that diminish beam hardening artefacts to substantially preserve the appearance of the device under CT or other corresponding imaging beam.
- stent 150 (or other medical devices according to the present invention) be made from a material or materials to have an overall image density of less than about 1200 Hounsfield Units. Such medical devices can also have an overall image density of less than about 900 Hounsfield Units. Such medical devices can also have an overall image density of less than about 700 Hounsfield Units. Such medical devices can also have an overall image density of less than about 400 Hounsfield Units.
- the medical devices within the scope of the invention include devices for the treatment of obstruction due to clot, plaque, atheroma, tumours or the like, and/or treatments involving intimal hyperplasia and recurrent stenosis after stent placement.
- An appropriate device is delivered into the vascular or bilary system under image guidance. The post placement follow up of the lumen is enabled by the diminished density and beam hardening artefact of the construct and coating of the stent.
- FIGS. 8 and 9 show a microcoil 250 for treatment of an aneurysm and which is introduced via a guiding cathether 240 and a microcatheter 245 .
- guiding cathether 240 is inserted through an incision 260 near the femoral artery or brachial artery or other suitable location and passed through the venous system of the patient until it reaches a blood vessel 264 proximal to an aneurysm 268 in the patient's head.
- FIG. 10 shows an image 254 of the resulting beam hardened artefact 252 when a prior art microcoil (not shown) is post-operatively examined using imaging system 30 has been previously inserted in the patient according to the method described in reference to FIG. 8 .
- the beam hardened artefact 252 thus renders it difficult, if not impossible, to accurately examine the prior art microcoil using imaging system 30 .
- microcoil 250 when microcoil 250 is inserted according to the method described with reference to FIG. 8 , then microcoil 250 , the now-repaired aneuryism 268 and blood vessel 264 leading thereto are all visible on display 42 and therefore capable of post-operative evaluation.
- FIG. 12 shows an image 454 of a sagittal view of patient along a plane that includes the carotid artery 470 of the patient.
- Image 454 is characterized by a beam hardened artefact 452 through which the lumen of an implanted prior art stent can be identified, but artefact 452 is severe enough to obscure the lumen of the carotid artery 470 , therefore preventing a determination as to whether restenosis is occurring in the lumen of artery 470 surrounding the prior art stent.
- FIG. 12 shows an image 454 of a sagittal view of patient along a plane that includes the carotid artery 470 of the patient.
- Image 454 is characterized by a beam hardened artefact 452 through which the lumen of an implanted prior art stent can be identified, but artefact 452 is severe enough to obscure the lumen of the carotid artery 470 , therefore preventing a determination as to whether restenosis is occurring in the lumen of
- stent 550 and the lumen of artery 470 surrounding the stent 550 can be viewed and the occurrence of restenonis determined.
- the specific structure and/or configuration and/or shape of stent 150 is chosen to further reduce the device's overall radiopacity.
- the weave of the stent's structure can be chosen to reduce the radiopacity, and therefore the measured level of Hounsfield units associated with the stent.
- Other aspects of the present invention provide a stent having a reduced number of passages of the stent or devices across the stenosis before dilating and deploying the stent in the stenosis. In certain prior art stents, it is necessary to cross the wire, pre-dilate, and deploy the stent posteriorly.
- a stent in accordance with an embodiment of the present invention can include a self-expanding yet balloon mounted and intelligently be restrained.
- the stent can be mounted on a balloon that is deployed by inflation of the balloon.
- Such a stent is self-expanding but is delivered on a balloon.
- the inflation of the balloon breaks the restraining polymeric bands and results in the self-expansion of the stent once the initial stimulus has been given.
- This polymeric material is drug-coated and thrombosis resistant. This polymeric material helps restrain plaque and potential embolic material behind the stent.
- the overall configuration of the stent has reduced beam hardened artifacts post insertion when viewed under CT.
- the number of passages of hardware across the stent or devices across the stent is reduced from five (as found in prior art stents) to two (according to an embodiment of the present invention) and thus, restrain against the wall of the vessel deep to the stent the material that would otherwise become potentially an embolic source. This can be helpful in reducing the risks of stroke after carotid stenting and in some circumstances can help reduce the need for distal flow protection devices which themselves have stroke risk.
- shunt 150 is coated (either in its entirety or in particular locations) with an opacifier to temporarily increase the Hounsfield units associated with shunt 150 during its insertion, to allow shunt 150 to be inserted using traditional means.
- a coating would be configured to gradually abate and dissolve into the patient's blood stream, such that the radiopacity and associated Hounsfield units of stent 150 would decrease over time, such that under a post-operative CT evaluation, the Hounsfield units associated with stent 150 are low enough to allow proper visualization of the lumen of artery 58 surrounding stent 150 .
- Suitable materials for coating shunt 150 include gold, iodine, ionic and non ionic iodinated compounds, ethiodol, and lipiodol, barium, tungsten, tantalum, gadolinium. Whatever coating is chosen, the amount and rate of dissolving of the coating is chosen to reduce toxicity experience by the patient during dissolution.
- the aforementioned coating is a hydrophilic polymer containing a restenosis inhibiting drug and a density enhancing radiologic material such as lyophilizied iodinated contrast material, which is embedded into the polymer.
- This coating is then placed over a stent 150 that is made from a suitable material such as a plastic or metal, such as stainless steel, inconel or metal glass (materials already approved by The United States of America Food and Drug Administration), or an optimal arrangement of strands of another metal can be used.
- stent 150 is both drug eluting and density eluting (i.e. the level of Hounsfield units associated with the stent decreases over time.)
- certain post processing software is provided in image processing unit 38 to maximize vascular conspicuity in conjunction with the known Hounsfield units and other imaging properties associated with stent 150 or other medical device in accordance with the present invention.
- image processing unit 38 to maximize vascular conspicuity in conjunction with the known Hounsfield units and other imaging properties associated with stent 150 or other medical device in accordance with the present invention.
- a level of Hounsfield units associated with stent 150 is known, then upon detection by system 30 of an item within the patient at that particular level of Hounsfield units, then that information can be used to identify the item as stent 150 and then to further enhance the image of the surrounding vascular region based on the known imaging properties (ie. radiopacity, structure, etc.) and using known signal processing an filtering techniques.
- the stents, coils and other medical devices according to the present invention can be coated with a material to decrease the risk of infection and restenosis, using techniques and compounds described in EP0797988A2 and EP1155689A2 to Angiotech Pharmaceuticals Inc. of Canada, and the University of British Columbia.
- the present invention also provides certain novel methods for evaluating cervical and intracranial vascular stents using CT, including MDCTA, that is reliable and low cost and then to use these techniques for long term evaluation and outcome analysis of stenting. Sensitivity and specificity can then be determined for MDCTA by comparison to conventional catheter angiogram results.
- the radiographic density of the stent, coil or other device can be altered to enhance CT, X Ray, Ultrasound and MRI visibility of the lumen. For the purpose of enhanced accuracy of CT diagnostic imaging beam hardening artefacts will be reduced and/or minimized.
- the devices in the present invention are in contrast to prior art devices that have been developed for conventional fluoroscopy guidance and thus are of a radiodensity or radiopacity that exceeds the needs of CT for clear visualization, this excess density creates unwanted beam hardening artefact.
- the present invention allows for a relatively non-invasive means to visualize the lumen of a blood vessel surrounding a previously installed stent (or other site of an implanted medical device). Due to the reduced beam hardening artefacts of the stent, obscuration of the lumen is reduced. This results in the ability to visualize the lumen non-invasively as compared follow-ups conducted by invasive repeat catheter angiography, with its resultant risk of stroke, death and/or injury to an important vessel or to otherwise obscure a critical finding.
- CTA and CTP are relatively less invasive imaging modalities that have been shown to aid in the diagnosis and treatment of acute ischemic stroke. Both utilize high-speed spiral CT scanning and three-dimensional volumetric reconstruction software to create various types of images following injection of IV contrast solution.
- CTA can provide three-dimensional vascular delineation similar to other non-invasive techniques as well as visualization of adjacent non-vascular soft-tissue.
- CTA can also offer rapid volume acquisition, limited reconstruction artifact and scan completion during the period of peak intravascular contrast enhancement. Using CTA, it is often possible to see filling defect in a vessel as a result of contrast displacement by clot or thrombus.
- the sensitivity for detecting flow abnormality in vessels in the circle of Willis by CTA can be at least 89% when compared to digital subtraction angiography (“DSA”), and CTA does not carry the up to 5% risk of complication, and the up to 0.5% risk of permanent stroke that DSA has been shown to carry.
- DSA digital subtraction angiography
Abstract
The invention provides a stent made from a material operable to perform a stent's desired therapeutic functions, and also made from a material that has a radiopacity that substantially preserves the appearance of the stent when the stent is viewed under a CT imaging beam. Such a stent can allow for follow-up of the stent and the surrounding blood-vessel on CT.
Description
- This application is a Continuation application of U.S. patent application Ser. No. 13/919,537 filed on Jun. 17, 2013, now U.S. Pat. No. 9,028,543, which is a Continuation application of U.S. patent application Ser. No. 13/047,226 filed on Mar. 14, 2011, now U.S. Pat. No. 8,465,539, which is a Divisional application of U.S. patent application Ser. No. 10/727,667 filed on Dec. 5, 2003, now U.S. Pat. No. 7,927,368, which is a Continuation-In-Part of U.S. patent application Ser. No. 10/394,007 filed Mar. 23, 2003, now abandoned, and claims priority to U.S. Patent Application Ser. No. 60/366,530 filed Mar. 25, 2002 and U.S. Patent Application Ser. No. 60/366,529 filed Mar. 25, 2002, the disclosures of each of which are hereby incorporated herein by reference in their entireties.
- The present invention relates generally to surgery under image guided navigation and more particularly relates to a method, device and system for surgical implantation of a medical device or the like, and/or postoperative evaluation of an implanted medical device or the like under image guidance.
- Stroke and cardiac disease remain a major cause of morbidity and result in profound suffering and expense. Increased awareness and improvements in diagnostic procedures have significantly increased the diagnosis of cervical and intracranial and cardiac vascular stenosis. A vascular stenosis is now being treated endovascularly at a significantly increased frequency. However, follow-up has predominantly been by angiography which evaluates the vascular contour but not the vascular wall. It is invasive, time consuming and expensive. Preliminary studies suggest that stent evaluation and restenosis pathophysiology can also be evaluated with Multi-detector Computed Tomography Angiography (“MDCTA”) which would be a significant advantage of this technique over conventional angiography.
- More specifically, endovascular therapy has ushered in a new age of minimally invasive vascular treatment. Endovascular devices have been rapidly developed and refined. Present technologies have enabled precise deployment of stents in much smaller arteries and have become more flexible and compliant so they can be navigated through tortuosities. At the same time there has been a growing pool of physicians trained in modern endovascular therapies so services are more widely available. However, the monitoring of these patients has become suboptimal because it relies on conventional angiography which is invasive and expensive. It also requires the patient to spend a full day removed from their daily activities. It also requires that some patients on anticoagulation briefly discontinue their therapy or be admitted to the hospital for an extended period of time. New MDCTA technology has not been widely used or validated for follow up. However, preliminary case studies seem to indicate that this technology is likely to provide additional beneficial information about the vascular wall and stent not obtainable from conventional angiograms. MDCTA is also non-invasive, requires a minimal amount of time and is less costly. MDCTA now has an axial resolution less than 0.5 mm and with the proposed development of new protocols and algorithms for image processing, this will be a superior tool to evaluate stenting and the etiology of any restenosis or stent failures. In particular, it will likely be able to separate negative remodeling from neointimal growth. It will also be able to evaluate for stent deformity and wall apposition as well as remodeling. MDCTA should also be applicable to other endovascular procedures such as follow up for aneurysm coilings.
- Indeed MDCTA reflects a number of advances in medical imaging that allow real time and/or three-dimensional image gathering under Computed Tomography (“CT”), Magnetic Resonance Imaging (“MRI”) or the like. For example, CT scanners such as the Toshiba Acquillion multi detector are capable of generating images in three different areas at frame rates of 13 frames a second, to thereby generate a three-dimensional rendering of the target area. Indeed, this and other advances in CT have led to the development of new CT applications including CT Angiography (“CTA”), and CT Perfusion (“CTP”). These imaging modalities are rapidly developing into powerful tools in the diagnosis and treatment of both ischemic and hemorrhagic stroke and bilary occlusion. See, for example, the following prior art references:
- Kopp A F, Ohnesorge B, Flohr T, Georg C, Schroder S, Kuttner A, Martensen J, Claussen C D. [Cardiac multidetector-row CT: first clinical results of retrospectively ECG-gated spiral with optimized temporal and spatial resolution] Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 2000 May; 172(5):429-35.
- Ohnesorge B, Flohr T, Becker C, Knez A, Kopp A F, Fukuda K, Reiser M F. [Cardiac imaging with rapid, retrospective ECG synchronized multilevel spiral CT] Radiologe. 2000 February; 40(2):111-7
- Achenbach S, Moshage W, Ropers D, Nossen J, Bachmann K. Non-invasive coronary angiography with electron beam tomography: methods and clinical evaluation in post-PTCA follow-up Z Kardiol. 1997 February; 86(2):121-30.
- Becker C R, Schoepf U J, Reiser M F. Methods for quantification of coronary artery calcifications with electron beam and conventional CT and pushing the spiral CT envelope: new cardiac applications. Int J Cardiovasc Imaging. 2001 June; 17(3):203-11.
- Kopp A F, Schroeder S, Kuettner A, Baumbach A, Georg C, Kuzo R, Heuschmid M, Ohnesorge B, Karsch K R, Claussen C D. Non-invasive coronary angiography with high resolution multidetector-row computed tomography. Results in 102 patients. Eur Heart J. 2002 November; 23(21):1714-25.
- Achenbach S, Ulzheimer S, Baum U, Kachelriess M, Ropers D, Giesler T, Bautz W, Daniel W G, Kalender W A, Moshage W. Non-invasive coronary angiography by retrospectively ECG-gated multislice spiral CT. Circulation. 2000 Dec. 5; 102(23):2823-8.
- Knez A, Becker A, Becker C, Leber A, Boekstegers P, Reiser M, Steinbeck G. [Detection of coronary calcinosis with multislice spiral computerized tomography: an alternative to electron beam tomographyZ Kardiol. 2002 August; 91(8):642-9.
- Mahnken A H, Sinha A M, Wildberger J E, Krombach G A, Schmitz-Rode T, Gunther R W. [The influence of motion artifacts conditioned by reconstruction, on the coronary calcium score in multislice spiral CT] Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 2001 October; 173(10):888-92.
- However, despite these advances in medical device technology, and in particular stent technology and imaging technology, prior art stent technologies have certain limitations when viewed under such CT machines, particularly due to beam hardening artefacts that are typically present, which thereby obscure the image and obviate or reduce the effectiveness of the CT machine as a post-operative diagnostic tool
- Due to these present limitations using MDCTA, it is common to rely on classical angiography for postoperative evaluation of endovascular procedures, yet such angiographic methods are invasive and expensive. In the USA, an angiogram can cost up to $8000.00, yet a corresponding MDCTA could be offered for as little as $400.00. Additionally, endovascular ultrasound has significant associated risks and is not suitable for the small intracranial vessels. In the end, it is believed that MDCTA has the potential to provide good visualization of the lumen as well as the arterial wall and stent. MDCTA actually visualizes the stent better than fluoroscopy and will likely prove to be the preferred technique when background subtraction is used to increase vascular conspicuity. It is also believed that MDCTA would also enable more precise outcome evaluation and allow for investigation of the underlying pathophysiology as well as evaluation of the stents and devices used.
- Polymer or lipid based drug delivery systems that can deliver drugs at a defined rate for up to five years from a single treatment have revolutionized medical therapy. Drug coated coronary stents have been shown to decrease restenosis rates in large clinical trials. See for example, the following references:
- “Sirilimus eluting stents versus standard stents in patients with stenosis of the coronary artery”, Moses et al. New England Journal of Medicine, page 1315-1323 Oct. 2, 2003 Vol. 349, No. 14.
- “Paclitaxel stent coating inhibits meointimal hyperplasia at 4 weeks in a porcine model of restenosis”, Heldman et al. circulation 2001, 103-2289-95.
- “A Paclitaxel eluting stent for the prevention of coronary restenosis”, Park et al. New England Journal of Medicine 2003, Vol. 348, page 1537-45.
- With respect to the drug delivery systems there are several types available at this time. These are principally those that are biodegradable or those that are non biodegradable. Biodegradable polymers release their loaded agents as they break down, while the matrix of non-biodegradable polymers remain intact even after all of the therapeutic agent has been released. These polymers release their loaded material by a process of either bulk erosion or surface erosion and diffusion or degradation. The polymers and co-polymers that are available at the present time include ethylene vinyl acetate (“EVAc”), a hydrophilic non biodegradable polymer, and biodegradable polymers such as hydrophobic polymers such as poly[BIS(p-carboxyphenoxy)]propane-sebacic acid (“PCPP:SA”), hydrophilic polymers and fatty acid dimer-sebacic acid (“FAD:SA”) polymers that deliver drugs including hydrophilic drugs and compounds
- A process such as lyophilization can be used to load the polymer with the desired compound or drug or compounds or drugs. In this was PCPP:SA, a desired compound such as iodinated contrast material, and methyl chloride may undergo the lyophilization process to load the PCPP:SA with a material with the ability to attenuate x-ray radiation and be visible on a radiographic image.
- In a first aspect of the invention there is provided a medical device made from a material operable to perform a therapeutic function of the device and wherein the material allows three-dimensional visualization of a surrounding tissue when the medical device is inserted into the tissue and viewed under an imaging beam.
- It is therefore an object of the invention to provide a medical device that is viewable under certain imaging beams that obviates or mitigates at least one of the above-identified disadvantages of the prior art.
- The medical device can be a stent and the surrounding tissue can be a lumen of a blood vessel. The stent can have a coating of a radioopaque material prior to insertion such that the stent that can be viewed during a conventional angiographic x-ray DA/DSA insertion and wherein the coating diminishes after insertion such that the stent can be viewed under CT post insertion. The stent can be coated with at least one of an antibiotic and a chemotherapy drug. The stent can be coated with at least one drug selected from the group consisting of a drug that is therapeutically effective to decrease attachment of platelets to the stent and a drug that is therapeutically effective to decrease restenosis. The drug can be selected from the group consisting of aspirin, plavix or paclitaxel.
- In a particular implementation of the first aspect, the device can be selected from the group of devices for the treatment of obstruction due to clot, plaque, atheroma, tumours, and treatments involving intimal hyperplasia and recurrent stenosis.
- The material used to manufacture the medical device can be selected from the group consisting of plastic, composite carbon fiber and Inconel, nitinol, stainless steel, or a radio lucent material.
- The imaging system can be a substantially real-time CT machine, such as the Toshiba Acquillon.
- The medical device can have an image density of less than about 1200 Hounsfield Units. The image density can be less than about 900 Hounsfield Units. The image density can be less than about 700 Hounsfield Units. The image density can be less than about 400 Hounsfield Units.
- The medical device can be a microcoil and the surrounding tissue is an aneurysm repaired with the microcoil.
- The configuration and structure of the medical device can be chosen to combine with the properties of the chosen material to provide a reduced beam hardened artifact. For example, where the device is a stent and the struts of the stent can be aligned or otherwise configured to reduce the beam hardened artifact.
- In another aspect of the invention there is provided an imaging processing unit for a CT machine comprising:
- a means for receiving mutli-plane images of mammalian tissue;
- a database of known medical devices and associated properties of the devices;
- a means for determining whether an object detected in the received images matches with a known medical device in the database, the means for determining based on the associated properties;
- means for applying a filter to the received images to enhance an image of the tissue that surrounds the implanted medical device based on the known associated properties; and,
- means for presenting the image on an output device.
- The database of known medical devices can include at least one of a stent and a microcoil. The associated properties in the database can include a Hounsfield unit measurement of the device.
- Embodiments of the invention will now be discussed, by way of example only, with reference to the attached Figures, in which:
-
FIG. 1 is a representation of an imaging system; -
FIG. 2 is a side view of a prior art stent; -
FIG. 3 is a representation of a beam hardened artifact caused by the prior art stent ofFIG. 2 when viewed under the imaging system ofFIG. 1 ; -
FIG. 4 shows the beam hardened artifact ofFIG. 3 at a different angle; -
FIG. 5 shows the beam hardened artifact ofFIG. 4 at a different angle; -
FIG. 6 a side view of a stent in accordance with an embodiment of the invention; -
FIG. 7 is a representation of the stent ofFIG. 6 when viewed under the imaging system ofFIG. 1 ; -
FIG. 8 shows a microcoil in accordance with another embodiment of the invention; -
FIG. 9 is a partial view of the microcoil ofFIG. 8 ; -
FIG. 10 is a representation of a beam hardened artifact caused by a prior art microcoil when viewed under the imaging system ofFIG. 1 ; -
FIG. 11 is a representation of the microcoil ofFIG. 9 after insertion into a patient and when viewed under the imaging system ofFIG. 1 ; -
FIG. 12 is a representation of a beam hardened artifact caused by a prior art carotid stent when viewed under the imaging system ofFIG. 1 ; and, -
FIG. 13 is a representation of a carotid stent in accordance with another embodiment of the invention after the carotid stent has been inserted into a patient and when viewed under the imaging system ofFIG. 1 . - Referring now to
FIG. 1 , an imaging system is indicated generally at 30.Imaging system 30 comprises apatient chamber 34, animage processing unit 38 and adisplay 42.Imaging system 30 can be based on any known or established imaging technology, but in a present embodiment is based on computed tomography (CT) having substantially the same functionality as a machine like the Toshiba Acquillon. Thus,patient chamber 34 is operable to capture images of a patient P in at least three planes, andprocessing unit 38 is operable to assemble those captured images to present a three-dimensional rendering of a target area within patient P ondisplay 42. Images ondisplay 42 can be navigated and/or viewed using the mouse and keyboard attached to processingunit 38, allowing the user to view a target area within patient P from any number of views. While not shown inFIG. 1 ,image processing unit 38 can also be attached to other output devices in addition todisplay 42, such as a printer. Further,image processing unit 38 also typically includes a fixed storage device (such as a hard drive), a removable storage device (such as CD-Rewriter, or a tape drive) and a network interface card or other network interface means for connectingprocessing unit 38 to a network such as an intranet and/or the internet over which captured images can be delivered. - Referring now to
FIG. 2 , a prior art conventional coronary stent is indicated at 50.FIG. 2 showsstent 50 in isolation, however, for purposes of explaining the prior art, it is to be assumed thatstent 50 has been implanted in a coronary artery of patent P. -
FIG. 3 shows animage 54 rendered ondisplay 42 ofsystem 30 ofpatient P. Image 54 shows a beam hardenedartefact 52 as it is implanted inside a coronary artery 58 inside aheart 62 of patient P. The area identified as beam hardenedartefact 52 is an inaccurate reproduction ofstent 50 as it is implanted inside artery 58. Thebeam hardening artefact 52 is created by the material ofstent 50. Accordingly,system 30 is of limited value in performing post-operative evaluations ofstent 50 and for determining whether any restenosis has occurred of coronary artery 58. -
FIGS. 4 and 5 show additional images 54 a and 54 b, respectively, of different orientations ofheart 62, which are readily produced ondisplay 42 due to the imaging capability ofsystem 30. In each image 54 a and image 54 b,stent 50 and the surrounding artery 58 are inaccurately reproduced due tobeam hardening artefact 52 ofstent 50. Thus, notwithstanding the great flexibility ofsystem 30 in being able to provide a multiplicity of views ofheart 62, in itscurrent form stent 50 andsystem 30 do not provide meaningful images for post-operative evaluation of artery 58 and the progress of any restenosis that may be occurring in the lumen of artery 58 surroundingstent 50. -
FIG. 6 , shows a medical device in accordance with an embodiment of the invention as astent 150.Stent 150 from outward appearances is substantially the same asprior art stent 50, and indeed, in the present embodiment is designed to provide substantially the same mechanical and therapeutic functionality asprior art stent 50. However, in contrast toprior art stent 50,stent 150 is made from a material that has a selected radiopacity such that the appearance ofstent 150 is preserved whenstent 150 is exposed to the imaging beam ofsystem 30 and presented ondisplay 42. Thus, whenstent 150 is implanted inheart 62, then in animage 154 ofheart 62 generated bysystem 30, the appearance ofstent 150 will be maintained whenheart 62 andstent 150 are shown indisplay 42, as shown inFIG. 7 . Sinceimage 154 has no beam hardened artefacts, it is now possible to examine the lumen of artery 58 surroundingstent 150, and thereby allow for an examination thereof for restenosis. - As will be appreciated by those of skill in the art, presence or absence of a beam hardening artefact can be measured according to the properties of the imaging system being used and in relation to the Hounsfield units associated with the particular material or tissue being exposed to the imaging beam. A relation between the linear attenuation coefficient (.mu.) and the corresponding Hounsfield unit (H) can be expressed as:
-
H=.mu. Material−.mu. Water .mu. Water .times. 1000 ##EQU00001## - The value of the Hounsfield unit varies from −1000 (for air) to 1000 (for bone) to 3000, as more particularly shown in Table I.
- TABLE-US-00001 TABLE I.sup.1 Tissue Range of Hounsfield units Material Hounsfield Unit Air −1000 Lung −500 to −200 Fat −200 to −50 Water 0 Blood 25 Muscle 25 to 40 Bone 200 to 1000.sup.1 The foregoing equation and table is found in Principles of Computerized Tomographic Imaging Parallel CT, Fanbeam CT, Helical CT and Multislice CT by Marjolein van der Glas, Aug. 29, 2000, http://www.ph.tn.tudelft.nl/˜marlein/pdf/CT.pdf
- Thus, in certain imaging systems materials with Hounsfield units exceeding about 1000 can be prone to creating beam hardening artefacts. Thus, presently preferred materials from which
stent 150 can be manufactured to have reduced beam hardening artefacts include certain plastic, composite carbon fiber and Inconel metals that have similar mechanical properties toprior art stent 50 such that substantially the same therapeutic effect instent 150 is achieved as was available inprior art stent 50. In any event, the chosen material forstent 150 has a level of Hounsfield density that diminish beam hardening artefacts to substantially preserve the appearance of the device under CT or other corresponding imaging beam. - It is thus presently preferred that stent 150 (or other medical devices according to the present invention) be made from a material or materials to have an overall image density of less than about 1200 Hounsfield Units. Such medical devices can also have an overall image density of less than about 900 Hounsfield Units. Such medical devices can also have an overall image density of less than about 700 Hounsfield Units. Such medical devices can also have an overall image density of less than about 400 Hounsfield Units.
- As previously discussed, other medical devices are also within the scope of the present invention. The medical devices within the scope of the invention include devices for the treatment of obstruction due to clot, plaque, atheroma, tumours or the like, and/or treatments involving intimal hyperplasia and recurrent stenosis after stent placement. An appropriate device is delivered into the vascular or bilary system under image guidance. The post placement follow up of the lumen is enabled by the diminished density and beam hardening artefact of the construct and coating of the stent.
- A specific example of another medical device within the scope of the invention is shown in
FIGS. 8 and 9 , which shows amicrocoil 250 for treatment of an aneurysm and which is introduced via a guidingcathether 240 and amicrocatheter 245. As best seen inFIG. 8 , guidingcathether 240 is inserted through anincision 260 near the femoral artery or brachial artery or other suitable location and passed through the venous system of the patient until it reaches ablood vessel 264 proximal to ananeurysm 268 in the patient's head. (Further discussion of this procedure can be found in the Inventor's copending application entitled “Method and Apparatus for Reducing Exposure to an Imaging Beam” and filed in the US Patent Office on Mar. 3, 2003, the contents of which are incorporated herein by reference.) -
FIG. 10 shows an image 254 of the resulting beam hardenedartefact 252 when a prior art microcoil (not shown) is post-operatively examined usingimaging system 30 has been previously inserted in the patient according to the method described in reference toFIG. 8 . The beam hardenedartefact 252 thus renders it difficult, if not impossible, to accurately examine the prior art microcoil usingimaging system 30. - However, as seen in
image 354 shown inFIG. 11 , when microcoil 250 is inserted according to the method described with reference toFIG. 8 , then microcoil 250, the now-repairedaneuryism 268 andblood vessel 264 leading thereto are all visible ondisplay 42 and therefore capable of post-operative evaluation. - Another medical device within the scope of the invention is a carotid stent, for placement in the carotid artery.
FIG. 12 shows an image 454 of a sagittal view of patient along a plane that includes thecarotid artery 470 of the patient. Image 454 is characterized by a beamhardened artefact 452 through which the lumen of an implanted prior art stent can be identified, butartefact 452 is severe enough to obscure the lumen of thecarotid artery 470, therefore preventing a determination as to whether restenosis is occurring in the lumen ofartery 470 surrounding the prior art stent. However, as shown inFIG. 13 , when acarotoid stent 550 in accordance with an embodiment of the present invention is used,stent 550 and the lumen ofartery 470 surrounding thestent 550 can be viewed and the occurrence of restenonis determined. - In other embodiments of the invention, the specific structure and/or configuration and/or shape of stent 150 (or other medical device) is chosen to further reduce the device's overall radiopacity. For example, the weave of the stent's structure can be chosen to reduce the radiopacity, and therefore the measured level of Hounsfield units associated with the stent. Other aspects of the present invention provide a stent having a reduced number of passages of the stent or devices across the stenosis before dilating and deploying the stent in the stenosis. In certain prior art stents, it is necessary to cross the wire, pre-dilate, and deploy the stent posteriorly. As a further example, a stent in accordance with an embodiment of the present invention can include a self-expanding yet balloon mounted and intelligently be restrained. For example, the stent can be mounted on a balloon that is deployed by inflation of the balloon. Such a stent is self-expanding but is delivered on a balloon. The inflation of the balloon breaks the restraining polymeric bands and results in the self-expansion of the stent once the initial stimulus has been given. This polymeric material is drug-coated and thrombosis resistant. This polymeric material helps restrain plaque and potential embolic material behind the stent. The overall configuration of the stent has reduced beam hardened artifacts post insertion when viewed under CT.
- The number of passages of hardware across the stent or devices across the stent is reduced from five (as found in prior art stents) to two (according to an embodiment of the present invention) and thus, restrain against the wall of the vessel deep to the stent the material that would otherwise become potentially an embolic source. This can be helpful in reducing the risks of stroke after carotid stenting and in some circumstances can help reduce the need for distal flow protection devices which themselves have stroke risk.
- In another variation of the present invention,
shunt 150 is coated (either in its entirety or in particular locations) with an opacifier to temporarily increase the Hounsfield units associated withshunt 150 during its insertion, to allowshunt 150 to be inserted using traditional means. Such a coating would be configured to gradually abate and dissolve into the patient's blood stream, such that the radiopacity and associated Hounsfield units ofstent 150 would decrease over time, such that under a post-operative CT evaluation, the Hounsfield units associated withstent 150 are low enough to allow proper visualization of the lumen of artery 58 surroundingstent 150. Suitable materials forcoating shunt 150 include gold, iodine, ionic and non ionic iodinated compounds, ethiodol, and lipiodol, barium, tungsten, tantalum, gadolinium. Whatever coating is chosen, the amount and rate of dissolving of the coating is chosen to reduce toxicity experience by the patient during dissolution. - In a presently preferred embodiment, the aforementioned coating is a hydrophilic polymer containing a restenosis inhibiting drug and a density enhancing radiologic material such as lyophilizied iodinated contrast material, which is embedded into the polymer. This coating is then placed over a
stent 150 that is made from a suitable material such as a plastic or metal, such as stainless steel, inconel or metal glass (materials already approved by The United States of America Food and Drug Administration), or an optimal arrangement of strands of another metal can be used. The result is thatstent 150 is both drug eluting and density eluting (i.e. the level of Hounsfield units associated with the stent decreases over time.) - In another embodiment of the invention, certain post processing software is provided in
image processing unit 38 to maximize vascular conspicuity in conjunction with the known Hounsfield units and other imaging properties associated withstent 150 or other medical device in accordance with the present invention. For example, where a level of Hounsfield units associated withstent 150 is known, then upon detection bysystem 30 of an item within the patient at that particular level of Hounsfield units, then that information can be used to identify the item asstent 150 and then to further enhance the image of the surrounding vascular region based on the known imaging properties (ie. radiopacity, structure, etc.) and using known signal processing an filtering techniques. - While only specific combinations of the various features and components of the present invention have been discussed herein, it will be apparent to those skilled in the art that desired subsets of the disclosed features and components and/or alternative combinations of these features and components can be utilized, as desired. For example, the stents, coils and other medical devices according to the present invention can be coated with a material to decrease the risk of infection and restenosis, using techniques and compounds described in EP0797988A2 and EP1155689A2 to Angiotech Pharmaceuticals Inc. of Canada, and the University of British Columbia.
- The present invention also provides certain novel methods for evaluating cervical and intracranial vascular stents using CT, including MDCTA, that is reliable and low cost and then to use these techniques for long term evaluation and outcome analysis of stenting. Sensitivity and specificity can then be determined for MDCTA by comparison to conventional catheter angiogram results. The radiographic density of the stent, coil or other device can be altered to enhance CT, X Ray, Ultrasound and MRI visibility of the lumen. For the purpose of enhanced accuracy of CT diagnostic imaging beam hardening artefacts will be reduced and/or minimized. The devices in the present invention are in contrast to prior art devices that have been developed for conventional fluoroscopy guidance and thus are of a radiodensity or radiopacity that exceeds the needs of CT for clear visualization, this excess density creates unwanted beam hardening artefact.
- Furthermore, the present invention allows for a relatively non-invasive means to visualize the lumen of a blood vessel surrounding a previously installed stent (or other site of an implanted medical device). Due to the reduced beam hardening artefacts of the stent, obscuration of the lumen is reduced. This results in the ability to visualize the lumen non-invasively as compared follow-ups conducted by invasive repeat catheter angiography, with its resultant risk of stroke, death and/or injury to an important vessel or to otherwise obscure a critical finding. CTA and CTP are relatively less invasive imaging modalities that have been shown to aid in the diagnosis and treatment of acute ischemic stroke. Both utilize high-speed spiral CT scanning and three-dimensional volumetric reconstruction software to create various types of images following injection of IV contrast solution. CTA can provide three-dimensional vascular delineation similar to other non-invasive techniques as well as visualization of adjacent non-vascular soft-tissue. CTA can also offer rapid volume acquisition, limited reconstruction artifact and scan completion during the period of peak intravascular contrast enhancement. Using CTA, it is often possible to see filling defect in a vessel as a result of contrast displacement by clot or thrombus. The sensitivity for detecting flow abnormality in vessels in the circle of Willis by CTA can be at least 89% when compared to digital subtraction angiography (“DSA”), and CTA does not carry the up to 5% risk of complication, and the up to 0.5% risk of permanent stroke that DSA has been shown to carry.
- The above-described embodiments of the invention are intended to be examples of the present invention and alterations and modifications may be effected thereto, by those of skill in the art, without departing from the scope of the invention which is defined solely by the claims appended hereto.
Claims (1)
1. A stent, comprising:
a material having structure to provide three-dimensional visualization of a surrounding tissue when said stent is inserted into said tissue and viewed under an imaging beam, said stent having:
a single coating layer selected from a group consisting of: a hydrophilic polymer, a hydrophobic polymer, and a fatty acid polymer, and
a density enhancing radiologic opacifier embedded into said single coating layer, said single coating layer and said embedded opacifier material together providing a first Hounsfield image density suitable for viewing under a first image modality used during device insertion into a patient,
wherein said density enhancing radiologic opacifier material is configured to elute from said single coating layer so as to provide a second Hounsfield image density suitable for viewing under a second image modality used for subsequent visualization of surrounding tissue, and
wherein said single coating layer includes a restenosis inhibiting drug.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/709,220 US20150238663A1 (en) | 2002-03-25 | 2015-05-11 | Device viewable under an imaging beam |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36652902P | 2002-03-25 | 2002-03-25 | |
US36653002P | 2002-03-25 | 2002-03-25 | |
US10/394,007 US20030204248A1 (en) | 2002-03-25 | 2003-03-24 | Device viewable under an imaging beam |
US10/727,667 US7927368B2 (en) | 2002-03-25 | 2003-12-05 | Device viewable under an imaging beam |
US13/047,226 US8465539B2 (en) | 2002-03-25 | 2011-03-14 | Device viewable under an imaging beam |
US13/919,537 US9028543B2 (en) | 2002-03-25 | 2013-06-17 | Device viewable under an imaging beam |
US14/709,220 US20150238663A1 (en) | 2002-03-25 | 2015-05-11 | Device viewable under an imaging beam |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/919,537 Continuation US9028543B2 (en) | 2002-03-25 | 2013-06-17 | Device viewable under an imaging beam |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150238663A1 true US20150238663A1 (en) | 2015-08-27 |
Family
ID=46300467
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/727,667 Active 2026-08-28 US7927368B2 (en) | 2002-03-25 | 2003-12-05 | Device viewable under an imaging beam |
US13/047,226 Expired - Lifetime US8465539B2 (en) | 2002-03-25 | 2011-03-14 | Device viewable under an imaging beam |
US13/919,537 Expired - Lifetime US9028543B2 (en) | 2002-03-25 | 2013-06-17 | Device viewable under an imaging beam |
US14/709,220 Abandoned US20150238663A1 (en) | 2002-03-25 | 2015-05-11 | Device viewable under an imaging beam |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/727,667 Active 2026-08-28 US7927368B2 (en) | 2002-03-25 | 2003-12-05 | Device viewable under an imaging beam |
US13/047,226 Expired - Lifetime US8465539B2 (en) | 2002-03-25 | 2011-03-14 | Device viewable under an imaging beam |
US13/919,537 Expired - Lifetime US9028543B2 (en) | 2002-03-25 | 2013-06-17 | Device viewable under an imaging beam |
Country Status (1)
Country | Link |
---|---|
US (4) | US7927368B2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7526112B2 (en) | 2001-04-30 | 2009-04-28 | Chase Medical, L.P. | System and method for facilitating cardiac intervention |
US7727221B2 (en) | 2001-06-27 | 2010-06-01 | Cardiac Pacemakers Inc. | Method and device for electrochemical formation of therapeutic species in vivo |
JP4982369B2 (en) * | 2004-08-13 | 2012-07-25 | ラトガース,ザ ステート ユニバーシティ | Radiopaque polymeric stent |
WO2006036786A2 (en) * | 2004-09-27 | 2006-04-06 | Cook Incorporated | Mri compatible metal devices |
US20060276910A1 (en) * | 2005-06-01 | 2006-12-07 | Jan Weber | Endoprostheses |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US7937133B2 (en) | 2006-06-26 | 2011-05-03 | Boston Scientific Scimed, Inc. | Method for determining size, pathology, and volume of embolic material |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
EP2068782B1 (en) | 2006-09-15 | 2011-07-27 | Boston Scientific Limited | Bioerodible endoprostheses |
EP2081616B1 (en) | 2006-09-15 | 2017-11-01 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
JP2010503491A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Bioerodible endoprosthesis with biologically stable inorganic layers |
CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
DE602007010669D1 (en) | 2006-12-28 | 2010-12-30 | Boston Scient Ltd | HREN FOR THIS |
US7942686B2 (en) * | 2007-05-03 | 2011-05-17 | Deringer-Ney, Inc. | Electrical barrier and moisture seal for an implanted medical device |
US7690953B2 (en) * | 2007-05-03 | 2010-04-06 | Deringer-Ney, Inc. | Stackable electrical connection apparatus |
US8206175B2 (en) * | 2007-05-03 | 2012-06-26 | Deringer-Ney, Inc. | Visual indicator of proper interconnection for an implanted medical device |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
WO2009097221A2 (en) * | 2008-01-28 | 2009-08-06 | Deringer-Ney, Inc. | Palladium-based alloys for use in the body and suitable for mri imaging |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
WO2010101901A2 (en) | 2009-03-02 | 2010-09-10 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
EP2477690A4 (en) * | 2009-09-15 | 2013-06-05 | Deringer Ney Inc | Electrical connection system and method for implantable medical devices |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US8845959B2 (en) | 2010-08-16 | 2014-09-30 | Deringer-Ney, Inc. | Gold-based alloy, free of silver and tin, for dental copings or abutments |
US20130102832A1 (en) * | 2011-08-25 | 2013-04-25 | Seth A. Hoedl | Brachytherapy devices and related methods having microencapsulated brachytherapy materials |
US10980568B1 (en) | 2019-11-25 | 2021-04-20 | Izi Medical Products, Llc | Half handle bone access needle |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5702682A (en) * | 1995-12-01 | 1997-12-30 | Hercules Incorporated | Methods for preparing radiopaque medical devices |
US6585755B2 (en) * | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
Family Cites Families (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3721997A (en) * | 1972-07-17 | 1973-03-27 | Sterling L O Dell | Protective garment |
US3984696A (en) | 1974-12-11 | 1976-10-05 | Medi-Ray, Inc. | Radiation guard for X-ray table |
US4062518A (en) | 1976-11-10 | 1977-12-13 | General Electric Company | X-ray shielding device |
DK558178A (en) | 1978-12-12 | 1980-06-13 | Uno Plast As | SURGICAL INSTRUMENT |
US4391276A (en) * | 1980-12-16 | 1983-07-05 | Harrison Lazarus | Peritoneal catheter |
US4465069A (en) | 1981-06-04 | 1984-08-14 | Barbier Jean Y | Cranial insertion of surgical needle utilizing computer-assisted tomography |
EP0087957B1 (en) | 1982-02-27 | 1986-11-26 | Kuraray Co., Ltd. | Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component |
US5067957A (en) * | 1983-10-14 | 1991-11-26 | Raychem Corporation | Method of inserting medical devices incorporating SIM alloy elements |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5102417A (en) * | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4686962A (en) | 1986-07-03 | 1987-08-18 | Habley Medical Technology Corporation | Disposable cartridge assembly for hypodermically implanting a genitourinary prosthesis |
JPS63238872A (en) * | 1987-03-25 | 1988-10-04 | テルモ株式会社 | Instrument for securing inner diameter of cavity of tubular organ and catheter equipped therewith |
US4795458A (en) * | 1987-07-02 | 1989-01-03 | Regan Barrie F | Stent for use following balloon angioplasty |
US4994066A (en) * | 1988-10-07 | 1991-02-19 | Voss Gene A | Prostatic stent |
DE3918736C2 (en) | 1989-06-08 | 1998-05-14 | Christian Dr Vallbracht | Plastic-coated metal mesh stents |
US5169386A (en) * | 1989-09-11 | 1992-12-08 | Bruce B. Becker | Method and catheter for dilatation of the lacrimal system |
US5084022A (en) * | 1989-10-04 | 1992-01-28 | Lake Region Manufacturing Company, Inc. | Graduated guidewire |
US5308352A (en) * | 1989-11-17 | 1994-05-03 | Koutrouvelis Panos G | Stereotactic device |
US5064435A (en) * | 1990-06-28 | 1991-11-12 | Schneider (Usa) Inc. | Self-expanding prosthesis having stable axial length |
US5258020A (en) * | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
US5454788A (en) * | 1991-04-24 | 1995-10-03 | Baxter International Inc. | Exchangeable integrated-wire balloon catheter |
US5242455A (en) * | 1991-05-03 | 1993-09-07 | University Of Pittsburgh | Imaging fixation and localization system |
US5292339A (en) | 1991-06-14 | 1994-03-08 | Telectronics Pacing Systems, Inc. | Implantable pacemaker/cardioverter/defibrillator device and method incorporating multiple bradycardia support pacing rates |
US5211165A (en) | 1991-09-03 | 1993-05-18 | General Electric Company | Tracking system to follow the position and orientation of a device with radiofrequency field gradients |
AU669338B2 (en) * | 1991-10-25 | 1996-06-06 | Cook Incorporated | Expandable transluminal graft prosthesis for repair of aneurysm and method for implanting |
JPH07506263A (en) | 1991-11-25 | 1995-07-13 | タン,スー,ウィー | infant body support |
NL9200286A (en) * | 1992-02-17 | 1993-09-16 | Sven Ploem | IMPACT-FREE OPERATING SYSTEM FOR A MULTI-AXLE DRIVER MANIPULATOR. |
CA2131902C (en) * | 1992-03-13 | 2004-08-03 | Paul Martakos | Controlled porosity expanded polytetrafluoroethylene products and fabrication |
US5540712A (en) * | 1992-05-01 | 1996-07-30 | Nitinol Medical Technologies, Inc. | Stent and method and apparatus for forming and delivering the same |
ATE247435T1 (en) * | 1992-05-08 | 2003-09-15 | Schneider Usa Inc | STENT FOR THE OESOPHAGUS |
DE4222380A1 (en) | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | Endoprosthesis implantable percutaneously in a patient's body |
DE4223585A1 (en) | 1992-07-17 | 1994-01-20 | Amazonen Werke Dreyer H | Device for spreading agricultural material |
US5311883A (en) | 1992-11-06 | 1994-05-17 | Eleanor Sherman | Sanitary shield for dedicated mammography apparatus |
US5335663A (en) * | 1992-12-11 | 1994-08-09 | Tetrad Corporation | Laparoscopic probes and probe sheaths useful in ultrasonic imaging applications |
DK0797988T3 (en) | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogenic compositions and methods for their use |
US5444871A (en) * | 1993-07-26 | 1995-08-29 | Johnson & Johnson Medical, Inc. | Medical gown with seamless sleeve protector |
US5735892A (en) * | 1993-08-18 | 1998-04-07 | W. L. Gore & Associates, Inc. | Intraluminal stent graft |
US5590655A (en) * | 1993-09-20 | 1997-01-07 | Hussman; Karl L. | Frameless laser guided stereotactic localization system |
US5531737A (en) | 1993-10-05 | 1996-07-02 | Schade; Christy M. | Surgical x-ray instrument for guiding needles |
US5989280A (en) | 1993-10-22 | 1999-11-23 | Scimed Lifesystems, Inc | Stent delivery apparatus and method |
US5403341A (en) * | 1994-01-24 | 1995-04-04 | Solar; Ronald J. | Parallel flow endovascular stent and deployment apparatus therefore |
US5549635A (en) * | 1994-01-24 | 1996-08-27 | Solar, Rita & Gaterud, Ltd. | Non-deformable self-expanding parallel flow endovascular stent and deployment apparatus therefore |
JP2825452B2 (en) * | 1994-04-25 | 1998-11-18 | アドヴァンスド カーディオヴァスキュラー システムズ インコーポレーテッド | Radiopak stent marker |
US5545150A (en) | 1994-05-06 | 1996-08-13 | Endoscopic Concepts, Inc. | Trocar |
US5482043A (en) | 1994-05-11 | 1996-01-09 | Zulauf; David R. P. | Method and apparatus for telefluoroscopy |
US5522881A (en) * | 1994-06-28 | 1996-06-04 | Meadox Medicals, Inc. | Implantable tubular prosthesis having integral cuffs |
DE69534862T2 (en) * | 1994-10-07 | 2006-08-17 | St. Louis University | Surgical navigation arrangement including reference and location systems |
US6978166B2 (en) * | 1994-10-07 | 2005-12-20 | Saint Louis University | System for use in displaying images of a body part |
US5522882A (en) * | 1994-10-21 | 1996-06-04 | Impra, Inc. | Method and apparatus for balloon expandable stent-graft delivery |
US5779688A (en) * | 1994-10-28 | 1998-07-14 | Intella Interventional Systems, Inc. | Low profile balloon-on-a-wire catheter with shapeable and/or deflectable tip and method |
US5857997A (en) * | 1994-11-14 | 1999-01-12 | Heart Rhythm Technologies, Inc. | Catheter for electrophysiological procedures |
US5556414A (en) * | 1995-03-08 | 1996-09-17 | Wayne State University | Composite intraluminal graft |
BE1009278A3 (en) * | 1995-04-12 | 1997-01-07 | Corvita Europ | Guardian self-expandable medical device introduced in cavite body, and medical device with a stake as. |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5788707A (en) * | 1995-06-07 | 1998-08-04 | Scimed Life Systems, Inc. | Pull back sleeve system with compression resistant inner shaft |
US5592952A (en) | 1995-08-18 | 1997-01-14 | Bohn; William W. | Infection control surgical drape and method of making surgical incision |
US5638819A (en) * | 1995-08-29 | 1997-06-17 | Manwaring; Kim H. | Method and apparatus for guiding an instrument to a target |
US5546961A (en) * | 1995-10-10 | 1996-08-20 | Harrison; Samuel W. | Sterility maintenance cover and instrument support |
US5591195A (en) * | 1995-10-30 | 1997-01-07 | Taheri; Syde | Apparatus and method for engrafting a blood vessel |
US5788626A (en) * | 1995-11-21 | 1998-08-04 | Schneider (Usa) Inc | Method of making a stent-graft covered with expanded polytetrafluoroethylene |
US5733326A (en) | 1996-05-28 | 1998-03-31 | Cordis Corporation | Composite material endoprosthesis |
US6027528A (en) | 1996-05-28 | 2000-02-22 | Cordis Corporation | Composite material endoprosthesis |
US5797952A (en) * | 1996-06-21 | 1998-08-25 | Localmed, Inc. | System and method for delivering helical stents |
US5902254A (en) | 1996-07-29 | 1999-05-11 | The Nemours Foundation | Cathether guidewire |
US5922020A (en) * | 1996-08-02 | 1999-07-13 | Localmed, Inc. | Tubular prosthesis having improved expansion and imaging characteristics |
US5800517A (en) * | 1996-08-19 | 1998-09-01 | Scimed Life Systems, Inc. | Stent delivery system with storage sleeve |
US5772669A (en) * | 1996-09-27 | 1998-06-30 | Scimed Life Systems, Inc. | Stent deployment catheter with retractable sheath |
US5824045A (en) * | 1996-10-21 | 1998-10-20 | Inflow Dynamics Inc. | Vascular and endoluminal stents |
US6086610A (en) * | 1996-10-22 | 2000-07-11 | Nitinol Devices & Components | Composite self expanding stent device having a restraining element |
US5676159A (en) | 1996-11-05 | 1997-10-14 | Janin Group | Ultrasound cover |
WO1998020812A1 (en) * | 1996-11-15 | 1998-05-22 | Cook Incorporated | Splittable sleeve, stent deployment device |
US6010529A (en) * | 1996-12-03 | 2000-01-04 | Atrium Medical Corporation | Expandable shielded vessel support |
EP2298241A3 (en) | 1996-12-03 | 2011-11-02 | Atrium Medical Corporation | Multi-stage prothesis |
US5925074A (en) * | 1996-12-03 | 1999-07-20 | Atrium Medical Corporation | Vascular endoprosthesis and method |
US6315791B1 (en) * | 1996-12-03 | 2001-11-13 | Atrium Medical Corporation | Self-expanding prothesis |
US6352561B1 (en) * | 1996-12-23 | 2002-03-05 | W. L. Gore & Associates | Implant deployment apparatus |
US5957974A (en) | 1997-01-23 | 1999-09-28 | Schneider (Usa) Inc | Stent graft with braided polymeric sleeve |
WO1998036688A1 (en) * | 1997-02-20 | 1998-08-27 | Johns Hopkins University | Friction transmission with axial loading and a radiolucent surgical needle driver |
US6146418A (en) * | 1997-02-28 | 2000-11-14 | Berman; Mark | Body implant and method of implanting |
US5906618A (en) * | 1997-03-20 | 1999-05-25 | Vanderbilt University | Microcatheter with auxiliary parachute guide structure |
US5876373A (en) * | 1997-04-04 | 1999-03-02 | Eclipse Surgical Technologies, Inc. | Steerable catheter |
US6143016A (en) | 1997-04-21 | 2000-11-07 | Advanced Cardiovascular Systems, Inc. | Sheath and method of use for a stent delivery system |
US5892238A (en) | 1997-05-02 | 1999-04-06 | Bionix Development Corp. | Radiation therapy shielding assembly |
US6075836A (en) * | 1997-07-03 | 2000-06-13 | University Of Rochester | Method of and system for intravenous volume tomographic digital angiography imaging |
US5899935A (en) | 1997-08-04 | 1999-05-04 | Schneider (Usa) Inc. | Balloon expandable braided stent with restraint |
ID26518A (en) | 1997-09-25 | 2001-01-11 | Minrad Inc | STERIL COVER |
US6059759A (en) * | 1997-10-14 | 2000-05-09 | Merit Medical Systems, Inc. | Infusion catheter systems with tactile sensing feedback |
US5980565A (en) * | 1997-10-20 | 1999-11-09 | Iowa-India Investments Company Limited | Sandwich stent |
US7070607B2 (en) * | 1998-01-27 | 2006-07-04 | The Regents Of The University Of California | Bioabsorbable polymeric implants and a method of using the same to create occlusions |
US6740113B2 (en) * | 1998-05-29 | 2004-05-25 | Scimed Life Systems, Inc. | Balloon expandable stent with a self-expanding portion |
US6374937B1 (en) | 1998-05-29 | 2002-04-23 | John Galando | Motorized support for imaging means and methods of manufacture and use thereof |
US6475234B1 (en) * | 1998-10-26 | 2002-11-05 | Medinol, Ltd. | Balloon expandable covered stents |
ATE239424T1 (en) * | 1998-12-16 | 2003-05-15 | Arthesys | CATHETER SYSTEM FOR HYDRAULIC RELEASE OF EMBOLIZATION CIRCUITS |
CA2593763C (en) | 1998-12-31 | 2008-11-18 | Kensey Nash Corporation | Tissue fastening devices and delivery means |
US6285902B1 (en) | 1999-02-10 | 2001-09-04 | Surgical Insights, Inc. | Computer assisted targeting device for use in orthopaedic surgery |
US6578219B1 (en) * | 1999-05-26 | 2003-06-17 | Kci Licensing, Inc. | Mattress overlay for operating room table |
US6456684B1 (en) * | 1999-07-23 | 2002-09-24 | Inki Mun | Surgical scanning system and process for use thereof |
US6533806B1 (en) * | 1999-10-01 | 2003-03-18 | Scimed Life Systems, Inc. | Balloon yielded delivery system and endovascular graft design for easy deployment |
US6544041B1 (en) | 1999-10-06 | 2003-04-08 | Fonar Corporation | Simulator for surgical procedures |
US6481888B1 (en) | 1999-10-12 | 2002-11-19 | R. Hank Morgan | Scatter ban drape |
US6379302B1 (en) * | 1999-10-28 | 2002-04-30 | Surgical Navigation Technologies Inc. | Navigation information overlay onto ultrasound imagery |
US6475235B1 (en) | 1999-11-16 | 2002-11-05 | Iowa-India Investments Company, Limited | Encapsulated stent preform |
US6355058B1 (en) * | 1999-12-30 | 2002-03-12 | Advanced Cardiovascular Systems, Inc. | Stent with radiopaque coating consisting of particles in a binder |
JP4172737B2 (en) * | 2000-02-03 | 2008-10-29 | インフォビジョン オプトエレクトロニクス ホールデングズ リミティッド | Liquid crystal element and method and apparatus for manufacturing the liquid crystal element |
JP3915862B2 (en) * | 2000-02-09 | 2007-05-16 | テルモ株式会社 | catheter |
US6325538B1 (en) | 2000-03-17 | 2001-12-04 | Christian M. Heesch | Radiation field isolator apparatus |
US6453185B1 (en) | 2000-03-17 | 2002-09-17 | Integra Lifesciences, Inc. | Ventricular catheter with reduced size connector and method of use |
US6689125B1 (en) | 2000-04-04 | 2004-02-10 | Spinalabs, Llc | Devices and methods for the treatment of spinal disorders |
US6484049B1 (en) * | 2000-04-28 | 2002-11-19 | Ge Medical Systems Global Technology Company, Llc | Fluoroscopic tracking and visualization system |
CA2403276C (en) * | 2000-05-04 | 2009-10-20 | Oregon Health Sciences University | Endovascular stent graft |
SE522805C2 (en) * | 2000-06-22 | 2004-03-09 | Jan Otto Solem | Stent Application System |
US6663650B2 (en) * | 2000-06-29 | 2003-12-16 | Concentric Medical, Inc. | Systems, methods and devices for removing obstructions from a blood vessel |
US6629992B2 (en) | 2000-08-04 | 2003-10-07 | Advanced Cardiovascular Systems, Inc. | Sheath for self-expanding stent |
US6448571B1 (en) * | 2000-08-15 | 2002-09-10 | James A. Goldstein | Radiation protection system |
US6412851B1 (en) | 2000-08-29 | 2002-07-02 | Jay Burks | Retractable cover for small vehicles |
CA2356032C (en) * | 2000-08-30 | 2004-08-17 | John A. Cowan | Shunt |
US6679886B2 (en) | 2000-09-01 | 2004-01-20 | Synthes (Usa) | Tools and methods for creating cavities in bone |
US6635064B2 (en) | 2000-10-04 | 2003-10-21 | Macropore Biosurgery, Inc. | Non-scatterable, radio-opaque material for medical imaging applications |
US20040132131A1 (en) * | 2001-11-05 | 2004-07-08 | Ofer Markman | Methods for comparitive analysis of carbohydrate polymers and carbohydrate polymers identified using same |
US6917827B2 (en) * | 2000-11-17 | 2005-07-12 | Ge Medical Systems Global Technology Company, Llc | Enhanced graphic features for computer assisted surgery system |
US6511471B2 (en) * | 2000-12-22 | 2003-01-28 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
US6899727B2 (en) | 2001-01-22 | 2005-05-31 | Gore Enterprise Holdings, Inc. | Deployment system for intraluminal devices |
US6716238B2 (en) | 2001-05-10 | 2004-04-06 | Scimed Life Systems, Inc. | Stent with detachable tethers and method of using same |
US6749628B1 (en) * | 2001-05-17 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Stent and catheter assembly and method for treating bifurcations |
US20040241094A1 (en) | 2001-09-13 | 2004-12-02 | Hesson Chung | Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
US6961606B2 (en) | 2001-10-19 | 2005-11-01 | Koninklijke Philips Electronics N.V. | Multimodality medical imaging system and method with separable detector devices |
US20030100830A1 (en) | 2001-11-27 | 2003-05-29 | Sheng-Ping Zhong | Implantable or insertable medical devices visible under magnetic resonance imaging |
AU2003228890A1 (en) | 2002-05-08 | 2003-11-11 | Abbott Laboratories | Endoprosthesis having foot extensions |
EP1362603B1 (en) | 2002-05-14 | 2006-03-01 | Terumo Kabushiki Kaisha | Coated stent for release of active agents |
KR100533458B1 (en) | 2002-07-20 | 2005-12-07 | 대화제약 주식회사 | Composition for solubilization of paclitaxel and preparation method thereof |
KR100533460B1 (en) | 2002-07-20 | 2005-12-08 | 대화제약 주식회사 | Mucoadhesive composition and formulation for solubilization of insoluble drugs and preparation method thereof |
US7575571B2 (en) * | 2002-10-29 | 2009-08-18 | Medtronic, Inc. | Indexing cell delivery catheter |
ATE377398T1 (en) | 2002-11-22 | 2007-11-15 | Cook Inc | STENT VESSEL TRANSPLANT |
US20040148000A1 (en) * | 2003-01-24 | 2004-07-29 | Bilge Fertac H. | Self expanding stent delivery system with balloon |
US20040176682A1 (en) * | 2003-03-03 | 2004-09-09 | Murphy Kieran P. | Method and apparatus for reducing exposure to an imaging beam |
-
2003
- 2003-12-05 US US10/727,667 patent/US7927368B2/en active Active
-
2011
- 2011-03-14 US US13/047,226 patent/US8465539B2/en not_active Expired - Lifetime
-
2013
- 2013-06-17 US US13/919,537 patent/US9028543B2/en not_active Expired - Lifetime
-
2015
- 2015-05-11 US US14/709,220 patent/US20150238663A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5702682A (en) * | 1995-12-01 | 1997-12-30 | Hercules Incorporated | Methods for preparing radiopaque medical devices |
US6585755B2 (en) * | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
Non-Patent Citations (1)
Title |
---|
Shenguo Wang et al., "Biodegradable Ploylactone-Family Plolymers and Their Applications in Medical Field", 17-30 November 2005, 8th Arab International Conference on Polymer Science & Technology, 17-30 November 2005, 15 pages. * |
Also Published As
Publication number | Publication date |
---|---|
US20110166645A1 (en) | 2011-07-07 |
US20130282109A1 (en) | 2013-10-24 |
US7927368B2 (en) | 2011-04-19 |
US8465539B2 (en) | 2013-06-18 |
US9028543B2 (en) | 2015-05-12 |
US20040153138A1 (en) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9028543B2 (en) | Device viewable under an imaging beam | |
US20050049672A1 (en) | Stent delivery system and method using a balloon for a self-expandable stent | |
US20030204248A1 (en) | Device viewable under an imaging beam | |
WO2007025266A2 (en) | Vascular graft marker | |
Sakai et al. | Descending thoracic aortic aneurysm: thoracic CT findings after endovascular stent-graft placement | |
Leclerc et al. | Helical CT for the follow-up of cervical internal carotid artery dissections. | |
Bruining et al. | Quantitative multi-modality imaging analysis of a bioabsorbable poly-L-lactic acid stent design in the acute phase: a comparison between 2-and 3D-QCA, QCU and QMSCT-CA. | |
Neri et al. | Spiral CT virtual endoscopy of abdominal arteries: clinical applications | |
Chabbert et al. | Midterm outcomes of thoracic aortic stent-grafts: complications and imaging techniques | |
Ruchat et al. | Endovascular treatment of aortic rupture by blunt chest trauma | |
Struffert et al. | Flat-detector computed tomography in the assessment of intracranial stents: comparison with multi detector CT and conventional angiography in a new animal model | |
EP1691721B1 (en) | Device viewable under an imaging beam | |
Truijers et al. | Endovascular aneurysm repair: state-of-art imaging techniques for preoperative planning and surveillance | |
CA2455439C (en) | Device viewable under an imaging beam | |
van den Berg et al. | Three-dimensional rotational angiography in peripheral endovascular interventions | |
Priestley et al. | Iatrogenic vertebral arteriovenous fistula treated with a hemobahn stent-graft | |
Arbab-Zadeh et al. | Hemodialysis access assessment with intravascular ultrasound | |
Peynircioglu et al. | Stent-graft applications in peripheral non-atherosclerotic arterial lesions | |
RU2216273C1 (en) | Method for detecting stenosis of visceral and renal arteries at thrombosed aneurysms of abdominal aorta | |
Laspas et al. | Imaging of coronary artery bypass grafts by computed tomography coronary angiography | |
US20220296249A1 (en) | Endovascular coil device for embolization of blood vessels | |
Reicher et al. | Vascular imaging for anaesthetists and intensivists, part 1: Basic principles | |
Haas | Implantation and imaging of coronary stents | |
Robinson | Developing post mortem computed tomography coronary angiography to investigate non-suspicious death | |
Kpodonu | Manual of thoracic endoaortic surgery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KIERAN MURPHY LLC, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MURPHY, KIERAN P.;REEL/FRAME:036573/0181 Effective date: 20150911 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |